Recommender systems are widely required and deployed to address real-world problems. In this paper, we study a new yet challenging real-world setting for recommender systems, where only user browsing histories are available without any explicit feedback. No item acquisition information, e.g., purchasing or rating, is given. By assuming that user browsing sequences are likely to contain the items to acquire, we draw an analogy to the setting of partial label learning in weakly supervised learning. This enables us to train reliable recommender systems only using browsing histories. We term the proposed method as Partial Acquisition Recommender System (PARS). Empirical results on real-world benchmark datasets show the effectiveness of the proposed method. Surprisingly, we also show that the proposed method even surpasses some baselines using item acquisition information.

Cancer risk prediction is a cornerstone of personalized medicine that offers opportunities for early detection and preventive interventions. However, the current models are designed to predict cancer risk face several challenges. First, most rely on traditional statistical methods, which struggle to capture the complexity of genetic, family medical history, and lifestyle factors. Hence, the accuracy of these models is limited. Additionally, the models neglect to integrate multidimensional data sources, particularly genetic information like single nucleotide polymorphisms (SNPs), which could enhance prediction accuracy. Third, while the system might effectively predict risk, it cannot translate those predictions into actionable healthcare recommendations to reduce cancer risk. In this study, we address all three of these limitations. With a focus on six prevalent cancers—we extracted SNP data from the UK Biobank and designed a novel risk prediction model for cancer and personalized healthcare recommendations based upon the mixture of experts (MoE) paradigm and large language models (LLMs), respectively. Named MoE-HRS, experts based two router networks for separate processing by the Transformer and the convolutional neural network (CNN). Experiments on UK Biobank data show that our model outperforms state-of-the-art cancer risk prediction models. To bridge the gap between risk prediction and practical healthcare applications, we devised a healthcare recommender system powered by LLMs. This approach holds promise for enhancing early detection rates and promoting preventive healthcare management (relevant coding and data are available at https://github.com/bjtu-lucas-nlp/MoE-HRS ).

MOTIVATION: Drug repositioning (DR), identifying novel indications for approved drugs, is a cost-effective strategy in drug discovery. Despite numerous proposed DR models, integrating network-based features, differential gene expression, and chemical structures for high-performance DR remains challenging. RESULTS: We propose a comprehensive deep pretraining and fine-tuning framework for DR, termed DrugRepPT. Initially, we design a graph pretraining module employing model-augmented contrastive learning on a vast drug-disease heterogeneous graph to capture nuanced interactions and expression perturbations after intervention. Subsequently, we introduce a fine-tuning module leveraging a graph residual-like convolution network to elucidate intricate interactions between diseases and drugs. Moreover, a Bayesian multiloss approach is introduced to balance the existence and effectiveness of drug treatment effectively. Extensive experiments showcase the efficacy of our framework, with DrugRepPT exhibiting remarkable performance improvements compared to SOTA (state of the arts) baseline methods (improvement 106.13% on Hit@1 and 54.45% on mean reciprocal rank). The reliability of predicted results is further validated through two case studies, i.e. gastritis and fatty liver, via literature validation, network medicine analysis, and docking screening. AVAILABILITY AND IMPLEMENTATION: The code and results are available at https://github.com/2020MEAI/DrugRepPT.

Recommender systems are one of the most successful applications of using AI for providing personalized e-services to customers. However, data sparsity is presenting enormous challenges that are hindering the further development of advanced recommender systems. Although cross-domain recommendation partly overcomes data sparsity by transferring knowledge from a source domain with relatively dense data to augment data in the target domain, the current methods do not handle heterogeneous data very well. For example, using today’s cross-domain transfer learning schemes with data comprising clicks, ratings, user reviews, item metadata, and knowledge graphs will likely result in a poorly performing model. User preferences will not be comprehensively profiled, and accurate recommendations will not be generated. To solve these three challenges—handling heterogeneous data, avoiding negative transfer, and dealing with data sparsity—we designed a new end-to-end deep A dversarial M ulti-channel T ransfer network for C ross- D omain R ecommendation named AMT-CDR . Heterogeneous data is handled by constructing a cross-domain graph based on real-world knowledge graphs—we used Freebase and YAGO. Negative transfer is prevented through an adversarial learning strategy that maintains consistency across the different data channels. Data sparsity is addressed with an end-to-end neural network that considers data across multiple channels and generates accurate recommendations by leveraging knowledge from both the source and target domains. Extensive experiments on three dual-target cross-domain recommendation tasks demonstrate the superiority of AMT-CDR compared to eight state-of-the-art methods. All source code is available at https://github.com/bjtu-lucas-nlp/AMT-CDR .

The knowledge of phenotype-genotype associations is crucial for the understanding of disease mechanisms. Numerous studies have focused on developing efficient and accurate computing approaches to predict disease genes. However, owing to the sparseness and complexity of medical data, developing an efficient deep neural network model to identify disease genes remains a huge challenge. Therefore, we develop a novel deep neural network model that fuses the multi-view features of phenotypes and genotypes to identify disease genes (termed PDGNet). Our model integrated the multi-view features of diseases and genes and leveraged the feedback information of training samples to optimize the parameters of deep neural network and obtain the deep vector features of diseases and genes. The evaluation experiments on a large data set indicated that PDGNet obtained higher performance than the state-of-the-art method (precision and recall improved by 9.55 and 9.63 percent). The analysis results for the candidate genes indicated that the predicted genes have strong functional homogeneity and dense interactions with known genes. We validated the top predicted genes of Parkinson's disease based on external curated data and published medical literatures, which indicated that the candidate genes have a huge potential to guide the selection of causal genes in the 'wet experiment'. The source codes and the data of PDGNet are available at https://github.com/yangkuoone/PDGNet.